On October 1, 2025, Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic discovery solutions, announced it has raised an oversubscribed $23.4 million Series A financing led by Engine Ventures. Additional participating investors include Illumina Ventures, Lightchain Capital, Mass General Brigham Ventures, ACS BrightEdge, Binney Street Capital of Dana-Farber Cancer Institute, and Myeloma Solutions Fund. Wilson Sonsini Goodrich & Rosati advised Predicta on IP matters related to the transaction.

The funding will be used to expand Predicta’s team and CLIA-approved lab infrastructure, and advance commercialization of the company’s first test, GenoPredicta. It will also be used to further the development of other non-invasive diagnostic solutions for blood cancers and autoimmune diseases.

The Wilson Sonsini team that advised Predicta on IP matters related to the transaction includes:

Patents and Innovations
Laurie McNamara
Sean Reed
Khailee Marischuk
Sarah Cohen

Technology Transactions
Mark Bellomy

For more information, please see Predicta's news release.